PMID- 30105474
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20191210
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
VI  - 252
DP  - 2018
TI  - Phencyclidine-Based New Psychoactive Substances.
PG  - 261-303
LID - 10.1007/164_2018_124 [doi]
AB  - The serendipitous discovery of phencyclidine (PCP) in 1956 sets the stage for 
      significant research efforts that resulted in a plethora of analogs and 
      derivatives designed to explore the biological effects of this class. PCP soon 
      became the prototypical dissociative agent that eventually sneaked through the 
      doors of clinical laboratories and became an established street drug. Estimations 
      suggest that around 14 PCP analogs were identified as "street drugs" in the 
      period between the 1960s and 1990s. Fast forward to the 2000s, and largely 
      facilitated by advancements in electronic forms of communication made possible 
      through the Internet, a variety of new PCP analogs began to attract the attention 
      of communities interested in the collaborative exploration of these substances. 
      Traditionally, as was the case with the first-generation analogs identified in 
      previous decades, the substances explored represented compounds already known in 
      the scientific literature. As the decade of the noughties unfolded, a number of 
      new PCP-derived substances appeared on the scene, which included some analogs 
      that have not been previously recorded in the published literature. The aim of 
      this chapter is to present a brief introductory overview of substances that have 
      materialized as PCP-derived new psychoactive substances (NPS) in recent years and 
      their known pharmacology. Since N-methyl-D-aspartate receptor (NMDAR) antagonism 
      is implicated in mediating the subjective and mind-altering effects of many 
      dissociative drugs, additional data are included from other analogs not presently 
      identified as NPS.
FAU - Wallach, Jason
AU  - Wallach J
AD  - Department of Pharmaceutical Sciences, Substance Use Disorder Institute, 
      Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, 
      USA. j.wallach@usciences.edu.
FAU - Brandt, Simon D
AU  - Brandt SD
AD  - School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, 
      Liverpool, UK. s.brandt@ljmu.ac.uk.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Illicit Drugs)
RN  - 0 (Psychotropic Drugs)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
RN  - J1DOI7UV76 (Phencyclidine)
SB  - IM
MH  - Humans
MH  - Illicit Drugs/*pharmacology
MH  - Phencyclidine/*pharmacology
MH  - Psychotropic Drugs/*pharmacology
MH  - Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors
OTO - NOTNLM
OT  - Clinical
OT  - Designer drugs
OT  - Dissociatives
OT  - Forensic
OT  - NMDA receptor
OT  - NPS
OT  - Pharmacology
OT  - Phencyclidine
OT  - Toxicology
EDAT- 2018/08/15 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/08/15 06:00
PHST- 2018/08/15 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/08/15 06:00 [entrez]
AID - 10.1007/164_2018_124 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2018;252:261-303. doi: 10.1007/164_2018_124.